All NVK-002 Articles
-
3.3KClinicalVyluma CHAMP Pivotal Phase 3 Clinical Trial Q&A
sponsored content October 27, 2022 Vyluma aims to preserve the vision of a global population by providing meaningful and effective pharmaceutical ophthalmic...
-
4.7KLatest Myopia NewsNevakar and Théa Enter Licensing Agreement for NVK-002 Atropine in Europe
February 1, 2021 BRIDGEWATER, N.J. and Clermont-Ferrand, France – Nevakar Inc. and Laboratoires Théa entered an exclusive licensing agreement for the commercialization...
-
3.0KLatest Myopia NewsFirst Patient Completes Three-Year Enrollment in Nevakar’s Phase III CHAMP Study of NVK-002
November 9, 2020 Nevakar Inc., a biopharmaceutical company developing multiple products in the ophthalmic and injectable areas, announced today that the first...